This is a narrative review that explores the relationship between vitamin D and invasive fungal infections. The authors discuss how vitamin D may influence antifungal immune responses, primarily through the antimicrobial peptide LL-37, which is regulated by vitamin D in a species-specific manner.
Key findings from animal models suggest a potential role for vitamin D in modulating antifungal immunity, but the evidence is indirect. The review highlights that rodent studies cannot be directly extrapolated to humans because primates have a unique vitamin D response element in the CAMP gene that regulates LL-37 expression, a mechanism absent in rodents.
Limitations acknowledged by the authors include model limitations and species differences. The primate-specific CAMP vitamin D response element regulation constrains direct translation of rodent vitamin D-to-LL-37 findings to human fungal disease. No clinical trial data or pooled effect sizes are presented.
For clinicians, this review underscores that while vitamin D is often hypothesized to support immune function, its specific role in preventing or treating invasive fungal infections is not established. The evidence remains at a preclinical stage, and no practice recommendations can be drawn.
View Original Abstract ↓
Vitamin D–mediated regulation of antimicrobial peptides (AMPs) is an important focus in innate immunology and is aimed at elucidating the role of vitamin D in enhancing antimicrobial defense. AMPs are short protein chains that serve as a first line of defense against invading pathogens, including fungi, bacteria and viruses. Unlike conventional antibiotics, AMPs are produced endogenously and are less likely to induce antimicrobial resistance, making them promising candidates for treating infections caused by drug-resistant pathogens. Studies indicate that optimal vitamin D levels are essential for activating antimicrobial pathways and regulating AMPs that target multiple fungal pathogens. This article summarizes recent findings on vitamin D-induced AMPs in the context of invasive fungal infections. It also distinguishes vitamin D as a host immune modulator from vitamin D3 as a putative active antifungal compound, given that direct antifungal use is limited by supraphysiologic dosing requirements, pharmacologic impracticality, and risks of hypercalcemia and hyperphosphatemia, especially in patients with granulomatous diseases. Model limitations and species differences are also discussed, including primate-specific CAMP vitamin D response element regulation, which constrains direct translation of rodent vitamin D-to-LL-37 findings to human fungal disease. Current global fungal priority frameworks and resistance surveillance support emphasizing Candida, Aspergillus, and Cryptococcus in this review of invasive fungal disease and translational host-defense evidence, underscoring the relevance of these pathogens.